Fulcrum scraps sickle cell drug program after FDA raises cancer-risk concerns

Fulcrum Therapeutics will stop developing its experimental sickle-cell disease drug after the FDA raised cancer-risk concerns, leaving no viable regulatory path for the treatment. The decision removes a key pipeline asset and is a material setback for the company, though the news is primarily company-specific rather than sector-wide.

Analysis

Fulcrum Therapeutics will stop developing its experimental sickle-cell disease drug after the FDA raised cancer-risk concerns, leaving no viable regulatory path for the treatment. The decision removes a key pipeline asset and is a material setback for the company, though the news is primarily company-specific rather than sector-wide.